TW202511485A - 調節rps25基因之表現及/或其功能的反義寡核苷酸 - Google Patents
調節rps25基因之表現及/或其功能的反義寡核苷酸 Download PDFInfo
- Publication number
- TW202511485A TW202511485A TW113122108A TW113122108A TW202511485A TW 202511485 A TW202511485 A TW 202511485A TW 113122108 A TW113122108 A TW 113122108A TW 113122108 A TW113122108 A TW 113122108A TW 202511485 A TW202511485 A TW 202511485A
- Authority
- TW
- Taiwan
- Prior art keywords
- antisense oligonucleotide
- stranded antisense
- nucleic acid
- acceptable salt
- pharmaceutically acceptable
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-099439 | 2023-06-16 | ||
| JP2023099439 | 2023-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202511485A true TW202511485A (zh) | 2025-03-16 |
Family
ID=93852230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113122108A TW202511485A (zh) | 2023-06-16 | 2024-06-14 | 調節rps25基因之表現及/或其功能的反義寡核苷酸 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4729616A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024257847A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN121311591A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202511485A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024257847A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| AU2010312751B2 (en) | 2009-10-29 | 2014-07-24 | Osaka University | Bridged artificial nucleoside and nucleotide |
| EP2899197B1 (en) | 2012-09-21 | 2017-03-22 | Osaka University | Oligonucleotide and artificial nucleoside having guanidine bridge |
| EP3109254B1 (en) | 2014-02-18 | 2018-04-11 | Osaka University | Crosslinked nucleoside and nucleotide |
| ES2893114T3 (es) | 2015-02-04 | 2022-02-08 | Bristol Myers Squibb Co | Métodos para seleccionar moléculas terapéuticas |
| AU2018354195A1 (en) | 2017-10-23 | 2020-06-04 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disease |
| JP7441523B2 (ja) | 2019-02-01 | 2024-03-01 | 国立大学法人大阪大学 | 5’位修飾ヌクレオシドおよびそれを用いたヌクレオチド |
| TWI910261B (zh) | 2020-11-06 | 2026-01-01 | 日商住友製藥股份有限公司 | Rps25基因之表現及/或功能調節劑 |
| EP4335859A4 (en) | 2021-05-06 | 2025-07-30 | Luxna Biotech Co Ltd | METHOD FOR DESIGNING AN OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY |
-
2024
- 2024-06-14 JP JP2025528002A patent/JPWO2024257847A1/ja active Pending
- 2024-06-14 CN CN202480039651.3A patent/CN121311591A/zh active Pending
- 2024-06-14 TW TW113122108A patent/TW202511485A/zh unknown
- 2024-06-14 EP EP24823460.1A patent/EP4729616A1/en active Pending
- 2024-06-14 WO PCT/JP2024/021613 patent/WO2024257847A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2024257847A1 (cg-RX-API-DMAC7.html) | 2024-12-19 |
| CN121311591A (zh) | 2026-01-09 |
| EP4729616A1 (en) | 2026-04-22 |
| WO2024257847A1 (ja) | 2024-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220143064A1 (en) | Tau antisense oligomers and uses thereof | |
| US20180023081A1 (en) | Lna oligonucleotides with alternating flanks | |
| US20180312839A1 (en) | Methods and compositions for increasing smn expression | |
| CN112424353A (zh) | α-突触核蛋白反义寡核苷酸及其用途 | |
| CN112912500A (zh) | 用于调节atxn2表达的寡核苷酸 | |
| CN111819283A (zh) | 靶向α-突触核蛋白的反义寡核苷酸及其用途 | |
| CN112567033A (zh) | 用于调节Tau表达之寡核苷酸 | |
| CA3144063A1 (en) | Ppm1a inhibitors and methods of using same | |
| TWI910261B (zh) | Rps25基因之表現及/或功能調節劑 | |
| JP2021514182A (ja) | Tmem106b発現を調節するためのオリゴヌクレオチド | |
| US20250376687A1 (en) | Compositions and methods to treat neurological diseases | |
| EP4729616A1 (en) | Antisense oligonucleotide capable of regulating expression and/or function of rps25 gene | |
| EP4349987A1 (en) | Antisense nucleic acid | |
| HK40131699A (en) | Antisense oligonucleotide for modulating expression and/or function of rps25 gene | |
| ITMI20012367A1 (it) | Oligonucleotidi antisenso che regolano l'espressione del gene antiapoptotico bcl-2 | |
| HK40097491A (en) | Regulator for expression and/or function of rps25 gene | |
| WO2026048784A1 (ja) | Atxn7遺伝子の発現及び/又はその機能を調節するアンチセンス核酸 | |
| WO2021187540A1 (ja) | Scn1a遺伝子の発現及び/又は機能調節剤 | |
| US20250136990A1 (en) | Antisense oligonucleotides targeting adenosine kinase | |
| WO2025128816A1 (en) | Methods of modulating expression of ube3a gene | |
| WO2024257848A1 (ja) | 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法 | |
| WO2026009916A1 (ja) | 2本鎖オリゴヌクレオチド | |
| HK40106720A (en) | Antisense nucleic acid | |
| HK40039999A (en) | Alpha-synuclein antisense oligonucleoties and uses thereof | |
| HK40043583A (en) | Oligonucleotides for modulating atxn2 expression |